Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 441-447

  Mah, F S ^a   O'Brien, T ^b   Kim, T ^c   Torkildsen, G ^d,e,f  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

^d Andover Eye Associates   (United States)

^e ORA Clinical Research and Development   (United States)

^f NONE   (United States)

Author keywords

Allergic conjunctivitis; Dry eye; Ocular surface disease; Olopatadine

Indexed keywords

ARTIFICIAL TEAR; OLOPATADINE; PATADAY; UNCLASSIFIED DRUG;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRY EYE; FEMALE; FLUOROPHOTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; TEAR FILM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; DRY EYE SYNDROMES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SODIUM CHLORIDE; TREATMENT OUTCOME;

EID: 39749169725     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X261078     Document Type: Article

References (29)

1. Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocular Surface 2003;1:127-49
2. Weeks ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987;21:1-20
3. McCarthy CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998;105:1114-9
4. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology 2003;110:1096-101
5. Gupta SK, Gupta V, Joshi S, Tandon R. Subclinically dry eyes in urban Delhi: an impact of air pollution? Ophtalmologica 2002;216:368-71
6. Nelson JD. Simultaneous evaluation of tear turnover and corneal epithelial permeability by fluorophotometry in normal subjects and patients with keratoconjunctivitis sicca (KCS). Trans Am Ophthalmol Soc 1995;93:709-53
7. Fahim MM, Haji S, Koonapareddy CV, et al. Fluorophotometry as a diagnostic tool for the evaluation of dry eye disease. BMC Ophthalmol 2006;6:20
8. Abdul-Fattah AM, Bhargva HN, Korb DR, et al. Quantitative in vitro comparison of fluorescein delivery to the eye via impregnated strip and volumetric techniques. Invest Ophthalmol Vis Sci 1999;40(Suppl):S544
9. Marquardt R, Stodtmeiser R, Christ T. Modification of tear film break-up time test for increased reliability. In: Holly FJ, editor. The preocular tear film in health, disease, and contact lens wear. Lubbock (TX): Dry Eye Institute; 1986
10. Ousler GW, Gomes PJ, Welch D, Abelson MB. Methodologies for the study of ocular surface disease. The Ocular Surface 2005;3:143-54
11. Schindelar M, Ousler III GW, et al. Effect of tear film stability on ocular surface damage in a population of dry eye patients. Invest Ophthalmol Vis Sci 2005;46:E-4457
12. Ousler GW, Wilcox KA, Gupta G, et al. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004;93:460-4
13. Welch D, Ousler GW, Nally LA, et al. Ocular drying associated with oral antihistamines (loratadine) in the normal population - an evaluation of exaggerated dose effect. Adv Exp Med Biol 2002;506:1051-5
14. Torkildsen G, Abelson MB. Comparison of topical and systemic anti-allergy treatments relative to ocular dryness. Presented at ARVO, 2006
15. Crandall DC, Leopold IH. The influence of systemic drugs on tear film constituents. Ophthalmology 1979;86:115-25
16. Rios JD, Dartt DA, et al. Immunolocalization of muscarinic and VIP receptor subtypes and their role in stimulating goblet cell secretion. Invest Ophthalmol Vis Sci 1999;40:1102-11
17. Ousler III GW, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007;29:611-6
18. Krokhmal L, Gomes P, Welch D, Abelson MB. The incidence of dry eye with topical anti-allergic therapies. Invest Ophthalmol Vis Sci 2007;48 E-2300
19. Edwards MR, Pasquine T, Gross RD, Robertson SM. Low frequency of treatment-related ocular adverse events associated with olopatadine 0.2% (Pataday™) in clinical trials. Presented at WSAAI 2007
20. Welch D, Davis J, Torkildsen G, et al. The effect of olopatadine 0.1% on tear film stability. Presented at: Association for Research in Vision and Ophthalmology annual meeting; April 30-May 4, 2006; Ft. Lauderdale, FL
21. Dogru M, Osmen A, Ertürk H, et al. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Clin Ther 2002;24:1309-21
22. Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and antihistamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr Med Res Opin 2005;21:1377-87
23. Abelson MB, Greiner JV, Gomes P, et al. Olopatadine reduces the ocular itching and redness of allergic conjunctivitis 24 hours after instillation. Presented at Western Society of Allergy, Asthma & Immunology annual meeting; January 19-23, 2003; Wailea, Hawaii
24. Vogelson C, Abelson M, Pasquine T, et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc 2004;25:69-75
25. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens 2006;32:272-6
26. Code of Federal Regulations. Title 21, Vol. 5, Sec. 349. 12,349.3,349.6
27. Göbbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992;99:873-8
28. Malet F, Karsenti D, Pouliquen P. Preservative-free ocular hydrating agents in symptomatic contact lens wearers: saline versus PVP solution. Eye Contact Lens 2003;29: 38-43
29. Guillon M, Maissa C, Pouliquen P, Deval L. Effect of povidone 2% preservative-free eyedrops on contact lens wearers with computer visual syndrome: pilot study. Eye Contact Lens 2004;30:34-9